A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
PHASE2
This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized stu...
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
PHASE3
This is a Phase III, 2-arm, randomised, open-label, multicentre, global stu...
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
N/A
Non-small cell lung cancer (NSCLC) is the most common histological form, ac...
Status
Completed
Location
Medical oncology department, University Hospital, Tours
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
PHASE1
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose e...
Status
Recruiting
Location
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
PHASE2
This Phase 2, open-label, randomized study in non-small-cell lung cancer (N...
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
PHASE2
Effective later-line treatment options remain an unmet medical need for pat...